NCT00706238View on ClinicalTrials.gov

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 29, 2008

Primary Completion Date

January 19, 2011

Study Completion Date

January 19, 2011

Conditions
Melanoma
Interventions
BIOLOGICAL

GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A

IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.

Trial Locations (6)

1878

GSK Investigational Site, Quilmes

11527

GSK Investigational Site, Athens

C1425DTG

GSK Investigational Site, CABA

S2000KZE

GSK Investigational Site, Rosario

185 47

GSK Investigational Site, Athens

0310

GSK Investigational Site, Oslo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00706238 - MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | Biotech Hunter | Biotech Hunter